Loading…
Enlifta, LLC marketed dietary supplement products "Enlifta Mood Elevator" and "Enlifta Anxiety" with claims that established them as unapproved drugs under the Federal Food, Drug, and Cosmetic Act, including representations that they treat depression, function as "natural antidepressants," and provide relief for severe anxiety. The company violated FDA regulations by making disease-treatment claims on its website and Amazon product listings without obtaining required drug approval, thereby introducing misbranded and unapproved drug products into interstate commerce. The FDA conducted website reviews in December 2020 and February 2021 that identified these violations through the marketing language used to promote the products.